AQS

Aequus Reports Second Quarter 2023 Financial Highlights and General Update

Retrieved on: 
Wednesday, August 30, 2023
Marketing, Eye, OTCQB, G&A, AQS, MDSAP, Patient, Q4, Health Canada, YTD, PF, Pharmaceutical industry, Novartis, Second

Net losses decreased by 9.22 % in Second Quarter 2023 compared to the same period last year, with the Second Quarter 2023 net loss of $700,875 versus a $772,100 loss in the three months ended June 30, 2022 (“Second Quarter 2022”).

Key Points: 
  • Net losses decreased by 9.22 % in Second Quarter 2023 compared to the same period last year, with the Second Quarter 2023 net loss of $700,875 versus a $772,100 loss in the three months ended June 30, 2022 (“Second Quarter 2022”).
  • Highlights from the quarter are as follows:
    Sales and marketing costs for Second Quarter 2023 were $372,844 compared to $663,082 in Second Quarter 2022, a decrease of $290,238 or 44%.
  • The Company incurred research and development (“R&D”) expenses of $25,824 in Second Quarter 2023 compared to $7,945 in Second Quarter 2022.
  • General and administration (“G&A”) expenses were $353,584 in Second Quarter 2023 compared to $457,177 in Second Quarter 2022, a decrease of $103,593.

LogicMark Signs Manufacturing Agreement with U.S. based AQS to Provide New PERS Devices to the Care Economy

Retrieved on: 
Tuesday, August 29, 2023
Operation, Partnership, Electronics, Ageing, AQS, LGMK, Risk, Engineering, Environment, Video game

“Having an additional contract manufacturer based in the U.S. helps us diversify our risk and minimize supply chain disruptions, ensuring our customers have the products they need.

Key Points: 
  • “Having an additional contract manufacturer based in the U.S. helps us diversify our risk and minimize supply chain disruptions, ensuring our customers have the products they need.
  • With existing tariffs on imported products, manufacturing in the USA is now more competitive, which allows us to increase the number of cost effective customer solutions.
  • AQS – which is ISO 13485 certified – is one of the most highly respected and experienced full-service contract manufacturers in the electronics manufacturing sector.
  • The LogicMark partnership with AQS is expected to provide added flexibility to the Company’s product manufacturing operations as well as capacity to fulfill the needs of a growing care economy.

Aequus Announces Zimed PF Now Available in Canada

Retrieved on: 
Thursday, August 24, 2023
Glaucoma, OTCQB, Physician, AQS, Patient, Pharmacy, Pharmaceutical industry

VANCOUVER, British Columbia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS , OTCQB: AQSZF ), ) (“Aequus” or the “Company”), a specialty pharmaceutical company announced today, we are thrilled to announce the launch of Zimed® PF, the first preservative-free multi-dose Bimatoprost for glaucoma patients in Canada.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS , OTCQB: AQSZF ), ) (“Aequus” or the “Company”), a specialty pharmaceutical company announced today, we are thrilled to announce the launch of Zimed® PF, the first preservative-free multi-dose Bimatoprost for glaucoma patients in Canada.
  • "This marks a new growth phase for Aequus and the launch of a Preservative Free (PF) innovation that brings value to both physicians and patients in a large therapeutic eye category,” says Grant Larsen, Chief Commercial Officer for Aequus Pharmaceuticals Inc. Canada.
  • “An exciting product innovation, launched in multiple countries around the world, this product will be available at pharmacies across Canada in the coming weeks.”
    For more information, please visit www.ZimedPF.ca and join us in celebrating this milestone in glaucoma treatment.

Aequus Announces Zimed PF Website Launch

Retrieved on: 
Tuesday, August 22, 2023
Glaucoma, Telecanthus, OTCQB, COS, Physician, Patient, AQS, Pharmaceutical industry

VANCOUVER, British Columbia, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS , OTCQB: AQSZF ), ) (“Aequus” or the “Company”), a specialty pharmaceutical company, are thrilled to announce the launch of our user friendly education website for patients and professionals.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS , OTCQB: AQSZF ), ) (“Aequus” or the “Company”), a specialty pharmaceutical company, are thrilled to announce the launch of our user friendly education website for patients and professionals.
  • With a focus on elevated, interocular pressure, Glaucoma and Dry Eye Disease, this website features Zimed® PF, the first preservative-free multi-dose Bimatoprost available in Canada.
  • With an emphasis on user-friendly navigation and an engaging interface, the website ensures a seamless experience for all visitors.
  • "We are proud to bring this long-awaited innovation to the Canadian glaucoma community," said Doug Janzen, CEO of Aequus Pharma Canada.

Aequus Pharmaceutical Canada Announces a Pause in Sales of Evolve Intensive Eyedrops and Gel in Canada

Retrieved on: 
Friday, August 18, 2023
Certification, Notified body, Intensive word form, OTCQB, Patient, AQS, MDSAP, Medical device

VANCOUVER, British Columbia, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS , OTCQB: AQSZF ), ) (“Aequus” or the “Company”), a specialty pharmaceutical company announces the pause of sales of its Evolve Intensive eyedrop and Intensive gel products in Canada.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS , OTCQB: AQSZF ), ) (“Aequus” or the “Company”), a specialty pharmaceutical company announces the pause of sales of its Evolve Intensive eyedrop and Intensive gel products in Canada.
  • Until this process is completed, Aequus Pharmaceuticals will pause sales of the class leading Evolve® range of products in the Canadian market.
  • We look forward to Evolve® returning to patients in Canada as soon as MDSAP Certification is issued.
  • Aequus and Medicom Healthcare assure valued customers and eyecare professionals that the Evolve® Intensive eyedrops and gel will return to the Canadian market soon.

China Automotive Fragrance and Air Purification Systems Research Report 2023: Driving Wellness Innovations - Exploring the Integration of Fragrance and Air Purification - ResearchAndMarkets.com

Retrieved on: 
Friday, August 18, 2023
Automotive Manufacturing, Manufacturing, Vehicle Technology, Other Automotive, Automotive, GLE, IAPS, Valeo, International, Mercedes-Benz, S class, Filter (signal processing), Geely, Original equipment manufacturer, Symrise, IVI, AMG, CLS, AQS, NIO, Noetics, Toyota, Certification, WM, HVAC, NFC, Plasma, Denso, WeChat, BMW, UV, AIO, XPeng G9, GLS, Highlander, Architecture, Growth, HEPA, Filtration, OEM, Palladium, Rail transport, Heating, ventilation, and air conditioning, Perfume, Civil engineering, Givaudan, Venza

The "China Automotive Fragrance and Air Purification Systems Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Automotive Fragrance and Air Purification Systems Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.
  • From 2020 to 2023, the installations of automotive air purification and fragrance systems will sustain steady growth.
  • It is predicted that in 2023 the installations of automotive air purification systems will exceed 6 million units, and that of fragrance systems will reach 1.03 million units.
  • 1.2.2 Principle of Air Purification System: Sources of Pollution and Conventional Purification Process
    1.2.4 Major Air Purification Technologies:

Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%)

Retrieved on: 
Friday, July 7, 2023
Minority, IOP, MI, OTCQB, AQS, Ocular hypertension, Patient, PGA, Loan, Multilateral, Safety, Security (finance)

VANCOUVER, British Columbia, July 06, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announces today it has increased its debt by $400,000 to support the launch of Zimed® PF.

Key Points: 
  • VANCOUVER, British Columbia, July 06, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announces today it has increased its debt by $400,000 to support the launch of Zimed® PF.
  • Mr. Doug Janzen, Chairman and Chief Executive Officer of the Company, has agreed to provide financing to Aequus by way of an unsecured demand loan of C$400,000 (the “Loan”).
  • “We remain very excited about the commercial prospects for Zimed and these funds will be used to support operations as we work to a successful launch in August,” said Mr. Janzen.
  • This new product is the only multi-dose preservative free prostaglandin analog (PGA) on the market, offering patients the efficacy, convenience, and safety without the use of preservatives.

Gwangju Institute of Science and Technology Researchers Improve the Solubility of Redox Molecules for Enhanced Energy Storage Systems

Retrieved on: 
Friday, June 2, 2023
Volume Eight, ACS Energy Letters, HSE, Quinone, ECS, Gwangju Institute of Science and Technology, AQS, Solubility, Assistant, AQM, Electrode, HQ, HSE Faculty of Mathematics, Climate change, Hydrotrope, Guideline, 2018 Arkansas Issue 5, Research, Extractive metallurgy, N

This transition can be supported by improving the efficiency of energy storage systems for safer and stable operations, sustainability, high energy/ power density.

Key Points: 
  • This transition can be supported by improving the efficiency of energy storage systems for safer and stable operations, sustainability, high energy/ power density.
  • Research on this front has focused on molecular engineering approaches to the development of aqueous-based redox-enhanced electrochemical capacitors (redox ECs).
  • Redox ECs are a type of advanced hybrid electric double-layer capacitors that use redox-active molecules at the electrode-electrolyte interface to increase the energy density.
  • Now, researchers from Korea have used hydrotropic-supporting electrolyte (HSE) as an approach to enhancing the solubility of the organic redox-active species.

Aequus Provides General Update and First Quarter 2023 Financial Highlights

Retrieved on: 
Wednesday, May 31, 2023
Acceleration, KOL, Partnership, Tacrolimus, Optometry, OTCQB, Research, AQS, HCP, Sale, Ophthalmology, CRM, Pharmaceutical industry, Novartis, Q1

VANCOUVER, British Columbia, May 30, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the quarter ended March 31, 2023 (“First Quarter 2023”) and associated Company developments.

Key Points: 
  • VANCOUVER, British Columbia, May 30, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the quarter ended March 31, 2023 (“First Quarter 2023”) and associated Company developments.
  • “As anticipated, revenues for the quarter were reduced due to the completion of the Sandoz contract at the end of last year.
  • Aequus recorded a net loss of $744,323 for the three months ended March 31, 2023, which is 19% lower than the loss of $916,886 for the period ending March 31, 2022.
  • The Company realized a 132% increase in Evolve product sales during the three months ended March 31, 2023, relative to the prior year.

Aequus Provides General Update and Fiscal 2022 Financial Results

Retrieved on: 
Tuesday, May 2, 2023
KOL, Travel, Revision, Eye, OTCQB, AQS, HCP, Novartis, Patient, CRM, Research, Health Canada, Fiscal, Ophthalmology

The higher loss was primarily due lower revenue in Fiscal 2022 relative to Fiscal 2021.

Key Points: 
  • The higher loss was primarily due lower revenue in Fiscal 2022 relative to Fiscal 2021.
  • Sales and marketing costs in Fiscal 2022 were $2,226,181 when compared to $2,173,592 in Fiscal 2021, a change of 2% or $52,589.
  • Research and development included product development expenses in Fiscal 2022 of $168,714 compared to $296,848 in Fiscal 2021, a decrease of 43% or $128,134.
  • General and administration expenses in Fiscal 2022 were $,1,593,362 compared to $2,023,773 in Fiscal 2021, a decrease of 21% or $430,411.